WRBC
CTOR

W.R. Berkley Corp’s Citius Oncology CTOR Stock Holding History

W.R. Berkley Corp’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-530,497
Closed -$6.02M – 178
2024
Q2 		$6.02M Buy
530,497
+200
+0% +$2.24K 0.25% 58
2024
Q1 		$5.87M Buy
530,297
+114,402
+28% +$1.26M 0.33% 53
2023
Q4 		$4.55M Buy
415,895
+274,933
+195% +$2.99M 0.33% 52
2023
Q3 		$1.52M Buy
140,962
+4,874
+4% +$52K 0.1% 145
2023
Q2 		$1.43M Buy
136,088
+31,579
+30% +$330K 0.09% 144
2023
Q1 		$1.08M Buy
+104,509
New +$1.07M 0.07% 142

Other funds holding CTOR

YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

W.R. Berkley Corp's CTOR Position: Q3 2024 in Review

W.R. Berkley Corp sold out of Citius Oncology (CTOR) in Q3 2024, closing a stake of 530,497 shares — an estimated $6.02M sold.

W.R. Berkley Corp first reported a position in CTOR in Q1 2023 and held it in 6 quarters. The position peaked at $6.02M in Q2 2024. 7 funds tracked by Wall St. Rank hold CTOR as of Q3 2024.

  • W.R. Berkley Corp reported no remaining Citius Oncology position as of Q3 2024 after selling out during the quarter.
  • W.R. Berkley Corp sold 530,497 Citius Oncology shares in Q3 2024, an estimated $6.02M.
  • W.R. Berkley Corp first reported a position in Citius Oncology in Q1 2023 and held it in 6 quarters.
  • W.R. Berkley Corp's Citius Oncology position peaked at $6.02M in Q2 2024.
  • 7 funds tracked by Wall St. Rank held Citius Oncology as of Q3 2024.

Based on W.R. Berkley Corp's 13F filing for Q3 2024, filed 14 Nov 2024.